Bausch Health Companies Inc. (BHC): Price and Financial Metrics

Bausch Health Companies Inc. (BHC)

Today's Latest Price: $19.53 USD

0.36 (1.88%)

Updated Nov 27 5:00pm

Add BHC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BHC Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for BHC is 13.69 -- better than 97.78% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 45.26 for Bausch Health Companies Inc; that's greater than it is for 99.17% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Bausch Health Companies Inc is reporting a growth rate of -155.52%; that's higher than only 12.81% of US stocks.
  • Stocks that are quantitatively similar to BHC, based on their financial statements, market capitalization, and price volatility, are KFS, ATLC, HCHC, SEAS, and KODK.
  • BHC's SEC filings can be seen here. And to visit Bausch Health Companies Inc's official web site, go to

BHC Stock Price Chart Interactive Chart >

Price chart for BHC

BHC Price/Volume Stats

Current price $19.53 52-week high $31.97
Prev. close $19.17 52-week low $11.15
Day low $19.23 Volume 1,033,373
Day high $19.64 Avg. volume 4,830,948
50-day MA $17.43 Dividend yield N/A
200-day MA $17.88 Market Cap 6.94B

Bausch Health Companies Inc. (BHC) Company Bio

Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.

BHC Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$19.53$1.83 -90%

Below please find a table outlining a discounted cash flow forecast for BHC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bausch Health Companies Inc ranked in the 11th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Bausch Health Companies Inc, consider:

  • Interest coverage, a measure of earnings relative to interest payments, is -0.3; that's higher than merely 19.82% of US stocks in the Healthcare sector that have positive free cash flow.
  • The company's compound free cash flow growth rate over the past 5.69 years comes in at -0.17%; that's greater than merely 9.88% of US stocks we're applying DCF forecasting to.
  • 22% of the company's capital comes from equity, which is greater than just 7.25% of stocks in our cash flow based forecasting set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

RGEN, COO, EW, TEVA, and QGEN can be thought of as valuation peers to BHC, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

BHC Latest News Stream

Event/Time News Detail
Loading, please wait...

BHC Latest Social Stream

Loading social stream, please wait...

View Full BHC Social Stream

Latest BHC News From Around the Web

Below are the latest news stories about Bausch Health Companies Inc that investors may wish to consider to help them evaluate BHC as an investment opportunity.

Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List

LUMIFY® Recognized in the "Superstar" Category for Exceptional Sales and Growth LAVAL, QC, Oct. 1, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that BASES, a Nielsen Global…

PR Newswire | October 1, 2020

Eyewear Market to Reach USD 57.69 bn by 2024, Bausch Health Companies Inc and Carl Zeiss AG Emerge as Key Contributors to Growth | Technavio

LONDON--(BUSINESS WIRE)-- #EyewearMarket--The Global Eyewear Market will grow by USD 57.69 bn during 2020-2024

Business Wire | October 1, 2020

Andrew Left Talks Inovio, Fluidigm And His 'Biggest Mistake As A Short Seller'

Citron Research founder and activist short seller Andrew Left discussed his latest ideas during an appearance on Benzinga’s PreMarket Prep show Tuesday morning. Left has gained notoriety over the years for successfully betting against Bausch Health Companies Inc (NYSE: BHC ) (formerly Valeant Pharmaceuticals) and a number of fraudulent Chinese stocks, but has also come out positive on a number of stocks he believes are true winners. Short Ideas: One of Left’s current short positions is COVID-19 vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO ), which Left calls “Pinocchio Pharmaceuticals.” “They were pretty much told by the FDA they can not start Phase 2, so they’re stuck in Phase 1. Now we’re 30 years [with] no product,” Left said. “I don’t know why it’s worth anything more than c...

Benzinga | September 29, 2020

Bausch and Eton receive FDA approval for ophthalmic solution

Bausch Health Companies (BHC) and Eton Pharmaceuticals (ETON) announces that FDA approves Alaway Preservative Free ophthalmic solution antihistamine eye drops as the first OTC preservative-free formulation eye drop."We expect Alaway Preservative Free will be available for purchase in the Spring of 2021 at major retailers in time for the start of allergy...

Seeking Alpha | September 25, 2020

FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%

LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA)…

PR Newswire | September 25, 2020

Read More 'BHC' Stories Here

BHC Price Returns

1-mo 18.36%
3-mo 17.51%
6-mo 3.17%
1-year -30.84%
3-year 16.60%
5-year -80.23%
YTD -34.73%
2019 61.99%
2018 -11.12%
2017 43.11%
2016 -85.72%
2015 -28.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9841 seconds.